![conference banner](/images/conference-banner.jpeg)
Abstract
Blood Brain Barrier (BBB) represents a major hurdle for the delivery of bioactives in the brain. It serves as a major constraint for the entry of hydrophilic drugs and the efflux pumps present on its surface restrain the intracellular accumulation of pharmacological moieties in the brain. Nanoparticles (NPs) in this regard can serve as a potential module for ferrying large doses of drugs across the BBB. These can be coated at surfaces or fabricated with a targeting moiety, so as to gain access in the brain thus, minimizing the toxicity of therapy. Therefore, the NPs can serve as an exclusive dais for spatial and temporal distribution of pharmacological agents across the brain, escalating the probability of disease free survival. The current review explores the various possible mechanisms so that the NPs can gain access in the brain viz a viz adsorption, receptor mediated endocytosis, transcytosis, inhibiting p-glycoprotein efflux pump, membrane permeabilization effect and disrupting the BBB. The article also accounts the prospects of NPs to enhance the transport of therapeutic agents across the brain, providing refined drug delivery.
Keywords: Blood brain barrier, nanoparticles, adsorption, endocytosis, P-glycoprotein efflux pump, drug delivery
Current Pharmaceutical Design
Title: Nanoparticles as Novel Carrier for Brain Delivery: A Review
Volume: 15 Issue: 8
Author(s): Abhinav Agarwal, Narendra Lariya, Gauravkant Saraogi, Nidhi Dubey, Himanshu Agrawal and G. P. Agrawal
Affiliation:
Keywords: Blood brain barrier, nanoparticles, adsorption, endocytosis, P-glycoprotein efflux pump, drug delivery
Abstract: Blood Brain Barrier (BBB) represents a major hurdle for the delivery of bioactives in the brain. It serves as a major constraint for the entry of hydrophilic drugs and the efflux pumps present on its surface restrain the intracellular accumulation of pharmacological moieties in the brain. Nanoparticles (NPs) in this regard can serve as a potential module for ferrying large doses of drugs across the BBB. These can be coated at surfaces or fabricated with a targeting moiety, so as to gain access in the brain thus, minimizing the toxicity of therapy. Therefore, the NPs can serve as an exclusive dais for spatial and temporal distribution of pharmacological agents across the brain, escalating the probability of disease free survival. The current review explores the various possible mechanisms so that the NPs can gain access in the brain viz a viz adsorption, receptor mediated endocytosis, transcytosis, inhibiting p-glycoprotein efflux pump, membrane permeabilization effect and disrupting the BBB. The article also accounts the prospects of NPs to enhance the transport of therapeutic agents across the brain, providing refined drug delivery.
Export Options
About this article
Cite this article as:
Agarwal Abhinav, Lariya Narendra, Saraogi Gauravkant, Dubey Nidhi, Agrawal Himanshu and Agrawal P. G., Nanoparticles as Novel Carrier for Brain Delivery: A Review, Current Pharmaceutical Design 2009; 15 (8) . https://dx.doi.org/10.2174/138161209787582057
DOI https://dx.doi.org/10.2174/138161209787582057 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences
Current Neuropharmacology Synthesis of 6-Aryl-2,11-dihydro-3H-pyrrolo[1,2-e][1,2,4]triazolo[4,3-b] [1,2,5]triazepin-3-ones
Letters in Organic Chemistry The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Local Gene Delivery for Cancer Therapy
Current Gene Therapy Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Recent Advances on Antitumor Agents-loaded Polymeric and Lipid-based Nanocarriers for the Treatment of Brain Cancer
Current Pharmaceutical Design 3D-Bioprinting and AI-empowered Anatomical Structure Designing: A Review
Current Medical Imaging Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy
Current Medicinal Chemistry <i>In Vitro</i> Effects of Propofol on Cytotoxic, Apoptotic and PI3K-Akt Signaling Pathway Genes on Brain Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Recent Advances in the Development of Catalytic Inhibitors of Human DNA Topoisomerase IIα As Novel Anticancer Agents
Current Medicinal Chemistry Mechanosensitive Ion Channels as Drug Targets
Current Drug Targets - CNS & Neurological Disorders MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism